SCHEMBL6487573

SCHEMBL6487573

CCN(C)N(CC)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27857517 0.82
SCHEMBL21442584 0.79
SCHEMBL22416394 0.77 PRMT3 (0.35)
SCHEMBL8279894 0.77
SCHEMBL19554001 0.75 DNM1 (0.38)
SCHEMBL17624895 0.75 TP53 (0.37)
SCHEMBL9877397 0.74 DNM1 (0.30)
SCHEMBL2682823 0.74 DNM1 (0.30)
SCHEMBL4506753 0.71 MGLL (0.36)
SCHEMBL3865761 0.70 DNM1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3625219-A1 PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLYLCARBOXYAMIDES Bayer Aktiengesellschaft (DE) 2020-03-25 EP claimed
US-6939866-B2 Quinazoline derivatives ASTRAZENECA AB (SE) 2005-09-06 US claimed
US-4235981-A MODIFIED CYCLOPENTADIENE-MALEIC ANHYDRIDE COPOLYMER IN REACTIVE SOLVENT NIPPON OIL CO., LTD. (JP) 1980-11-25 US claimed
US-10583141-B2 N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2020-03-10 US disclosed
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF NATIONAL SCIENCE FOUNDATION 2018-07-05 US disclosed
US-20180155827-A1 Synthesis of Metal Nitride Thin Films Materials using Hydrazine Derivatives APPLIED MATERIALS, INC. 2018-06-07 US disclosed
US-8456396-B2 Liquid crystal display device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-06-04 US disclosed
US-6316482-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 US disclosed
EP-0832061-B1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-05 EP disclosed
US-6211242-B1 CARDIOVASCULAR DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-03 US disclosed
US-6207693-B1 Benzamide derivatives having a vasopressin antagonistic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 US disclosed
WO-1998024771-A1 BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-11 WO disclosed
EP-0832061-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-01 EP disclosed
EP-0757670-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-12 EP disclosed
WO-1996041795-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-12-27 WO disclosed
EP-0685489-A2 Tripeptide antithrombotic agents ELI LILLY AND COMPANY (US) 1995-12-06 EP disclosed
WO-1995029152-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-11-02 WO disclosed
US-4885299-A TREATMENT OF ENERGY INSUFFICIENCY AND CEREBRAL AGING ADIR ET CIE (FR) 1989-12-05 US disclosed
US-4859700-A 2-(2,3-dihydro-2-oxo-3-benzofuranyl)acetic acid compounds having antihypoxic and nootropic effects ADIR ET CIE (FR) 1989-08-22 US disclosed
US-3985757-A ANTIINFLAMMATORY AGENTS AND TRANQUILIZERS E. R. SQUIBB & SONS, INC. (US) 1976-10-12 US disclosed